Latest filing published 23 Sept 2026 for 삼익제약.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -26.1%Entry ₩10,960 · Close 07 Oct 2026 ₩8,100
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
권영이: trading record in brief
권영이 (chief executive) discloses dealings in 삼익제약 to DART (FSS). Between 7 January 2026 and 23 September 2026, the trades on record add up to 7 filings.
On the open market, the record shows 3 purchases worth €76k and 4 sales worth €90k. The totals do not cover 5 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
On 23 September 2026 came the latest disclosure, an open-market sale in 삼익제약. The last insider purchase was made public on 6 July 2026, 125 days ago. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Companies and markets linked to 권영이
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,000 sharesShareKRXDART:20260923000239
- 60,000 sharesShareKRXDART:20260706000106Canonical exit: 28 Sept 2026 (T+90)
- 15,000 sharesShareKRXDART:20260608000098
- 21,932 shares@ ₩7,163.26550.30% mcap54.0% of flowShareKRXDART:20260604000155
- 13,068 sharesShareKRXDART:20260519000026
- 25,000 shares@ ₩5,310.000.26% mcap46.0% of flowShareKRXDART:20260326000891Canonical exit: 24 Jun 2026 (T+90)
- 25,000 sharesShareKRXDART:20260106000712Canonical exit: 29 Mar 2026 (T+90)
7 of 7 declarations